Kosan Biosciences Incorporated operates as a biotechnology company that develops two classes of anticancer agents. It develops heat shock protein 90 (Hsp90) inhibitor, KOS-953, which is in Phase I and II clinical trials, primarily for multiple myeloma and HER2 positive breast cancer, as well as intravenous and oral formulations of its another Hsp90 inhibitor, KOS-1022, which is in Phase I clinical trial. The company also develops KOS-862 and KOS-1584 to treat breast cancer. KOS-862 is in Phase II clinical trials, and KOS-1584 is in Phase I clinical trials. In addition, Kosan Biosciences has a motilin receptor agonist program for the stimulation of gastrointestinal movement. It has a...